SCHEMBL4256006

SCHEMBL4256006

Cc1ccc(/C=C/S(=O)(=O)O)s1.NC(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 3/20 0.40
HPGD P15428 3/20 0.40
LMNA P02545 1/20 0.40
UBE2I P63279 1/20 0.40
SAE1 Q9UBE0 1/20 0.40
UBA2 Q9UBT2 1/20 0.40
SMN1; SMN2 Q16637 6/20 0.39
MAPT P10636 5/20 0.39
HTT P42858 3/20 0.39
NR2F2 P24468 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 2/20 0.38
USP2 O75604 1/20 0.38
ALOX15 P16050 1/20 0.38
FLT1 P17948 4/20 0.38
FLT4 P35916 4/20 0.38
KDR P35968 4/20 0.38
NPC1 O15118 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4257616 0.82 SMN1; SMN2 (0.40) ALDH1A1KDM4EHPGDSMN1; SMN2MAPT
SCHEMBL4256003 0.80 FLT1 (0.50) MEN1KMT2APOLBUSP2ALOX15
SCHEMBL4256009 0.80 FLT1 (0.50) MEN1KMT2APOLBUSP2ALOX15
SCHEMBL4255224 0.80 LMNA (0.48) ALDH1A1KDM4EHPGDLMNASMN1; SMN2
SCHEMBL5645876 0.79 PTGS1 (0.50) ALDH1A1KDM4EHPGDLMNAUBE2I
SCHEMBL5645747 0.79 PTGS1 (0.50) ALDH1A1KDM4EHPGDLMNAUBE2I
SCHEMBL4256675 0.79 FLT1 (0.40) ALDH1A1KDM4EHPGDSMN1; SMN2MAPT
SCHEMBL4618879 0.78 SMN1; SMN2 (0.44) ALDH1A1KDM4EHPGDSMN1; SMN2MAPT
SCHEMBL4261111 0.78 FLT1 (0.38) ALDH1A1KDM4EHPGDLMNASMN1; SMN2
SCHEMBL5417239 0.77 MAPT (0.43) ALDH1A1KDM4EHPGDLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP claimed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP disclosed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP1A1, CYP3A5 ALDH1A1 148/4885KDM4E 2160/4885HPGD 603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.